Everything You Need to Know from Neurologist Kenneth Wogensen, MD
Kensington Senior Living celebrates the recent FDA approval of Leqembi, a revolutionary new treatment for dementia. This breakthrough not only changes the landscape in the fight against Alzheimer’s, but it also offers a beacon of hope for our residents, their families, and millions of other aging adults living with this disease.
Don’t miss your chance to learn all about this groundbreaking new treatment. We are thrilled to partner with Neurologist Kenneth Wogensen, MD for a complimentary educational webinar. Whether you are an individual living with dementia, a family caregiver, a healthcare professional, or simply passionate about brain health, this event is for you!
What You Will Learn
Basic Science: How Leqembi Fights Amyloid Plaques in the Brain
Efficacy: Clinical Trials Results and FDA Approval Process
Impact: Who is Eligible and Why, Plus Side Effects
Accessibility: Medicare Coverage
And More!
Submit your top questions when you register, and get them answered live by Dr. Wogensen during our Q&A portion of the webinar. Secure your spot now, and let’s come together to explore the potential of Leqembi in the relentless pursuit of a world without Alzheimer’s.
Kenneth K. Wogensen, MD, is an experienced board-certified neurologist who has been providing expert care since 1988. He earned a medical degree from the University of California, Irvine, School of Medicine; completed his neurology residency at the University of San Diego School of Medicine; and participated in a fellowship in the Stanford Neurology Unit. He is a family-oriented physician who doesn’t just take care of the patient, but the entire family. He specializes in the medical management of dementia, Alzheimer’s disease, vertigo, myasthenia gravis, and seizures. He is currently affiliated with the Arcadia Methodist Hospital, serving as the director of the stroke program.
For questions about this event, please email Jodie Kendall, Director of Community Relations, at jkendall@kensingtonsl.com.
